Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,927,831
  • Shares Outstanding, K 105,575
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • 60-Month Beta 1.01
  • Price/Sales 14.90
  • Price/Cash Flow N/A
  • Price/Book 10.58
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 60.24% ( -5.91%)
  • Historical Volatility 36.45%
  • IV Percentile 69%
  • IV Rank 31.99%
  • IV High 115.58% on 04/15/24
  • IV Low 34.20% on 09/14/23
  • Put/Call Vol Ratio 0.60
  • Today's Volume 466
  • Volume Avg (30-Day) 774
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 15,240
  • Open Int (30-Day) 30,527

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 6
  • High Estimate -0.12
  • Low Estimate -0.21
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +57.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.09 +3.82%
on 05/20/24
73.77 -9.80%
on 05/02/24
-5.76 (-7.97%)
since 04/29/24
3-Month
63.30 +5.12%
on 03/14/24
84.89 -21.62%
on 04/16/24
-2.98 (-4.29%)
since 02/29/24
52-Week
45.50 +46.24%
on 10/30/23
84.89 -21.62%
on 04/16/24
+6.34 (+10.53%)
since 05/26/23

Most Recent Stories

More News
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 66.54 (+1.40%)
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024

Stocks that traded heavily or had substantial price changes on Tuesday: UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall

IP : 44.40 (-1.66%)
NTRS : 81.73 (-0.43%)
PNC : 151.16 (-0.77%)
ABX.TO : 23.23 (-2.39%)
LYV : 94.00 (-0.94%)
UNH : 484.72 (-3.76%)
ITCI : 66.54 (+1.40%)
MS : 97.27 (-1.42%)
Intra-Cellular: Q4 Earnings Snapshot

Intra-Cellular: Q4 Earnings Snapshot

ITCI : 66.54 (+1.40%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 66.54 (+1.40%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 66.54 (+1.40%)
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

ITCI : 66.54 (+1.40%)
RCUS : 15.15 (-3.32%)
ALLO : 2.33 (-4.12%)
OCUP : 1.7050 (+2.10%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 66.54 (+1.40%)
BCDA : 0.3449 (-1.46%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 66.54 (+1.40%)
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

ITCI : 66.54 (+1.40%)
ACAD : 14.62 (-3.11%)
AXSM : 75.21 (-2.02%)
APTX : 0.0960 (+3.11%)
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ITCI : 66.54 (+1.40%)
EXAS : 44.82 (-4.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 69.88
2nd Resistance Point 68.49
1st Resistance Point 67.51
Last Price 66.54
1st Support Level 65.14
2nd Support Level 63.75
3rd Support Level 62.77

See More

52-Week High 84.89
Fibonacci 61.8% 69.84
Last Price 66.54
Fibonacci 50% 65.19
Fibonacci 38.2% 60.55
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar